<a href="https://laohu8.com/S/APLM">Apollomics Inc</a>. Receives Nasdaq Delisting Notice, Will Appeal to Retain Listing Amid Ongoing Operations and New Funding
**Apollomics Inc. Faces Nasdaq Delisting, Plans to Appeal** Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company, announced it received a delisting notification from the Nasdaq Stock Market on September 18, 2025. The Nasdaq staff cited concerns that Apollomics is now only a "public shell" with no ongoing operating business, referencing a lack of personnel and uncertainty around staffing. Despite these concerns, Apollomics maintains that it is still an active pharmaceutical company and recently secured $4.1 million in new funding, appointed a new board of directors, and reversed previous plans to wind up its business. The company is continuing operations and focusing on advancing its oncology drug development programs, including the lead candidate, vebreltinib. Apollomics has announced that it will appeal the delisting decision in an effort to retain its Nasdaq listing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-217820), on September 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.